Mode
Text Size
Log in / Sign up
Phase 4 Completed N=250 Randomized Triple-blind Supportive Care

Study of the Effectiveness of Administration of Meperidine on the Length of Active Phase of Labor in Women

Source: ClinicalTrials.gov NCT01555671 ↗
Enrolled (actual)
250
Serious AEs
0.0%
Results posted
Sep 2021
Primary outcomePrimary: The Duration of Active Phase of Labour — 249; 304 minutes — p=0.029
◆ Published Evidence
Established
43citations · ~3 / year
A comparison between remifentanil and meperidine for labor analgesia: a systematic review.
Anesthesia and analgesia · 2011 · High-confidence link

Summary

This study aims to evaluate the effect of meperidine on the length of active phase of labor in nulliparous or multiparous women, who will be randomized into two (control and study) groups. Our hypothesis is that the use of meperidine during active labor has no effect on the duration of labor.

Linked Publications (4)

  • A comparison between remifentanil and meperidine for labor analgesia: a systematic review.
    Anesthesia and analgesia · 2011 · 43 citations · High-confidence link
  • Effect of pethidine administered during the first stage of labor on the acid-base status at birth.
    European journal of obstetrics, gynecology, and reproductive biology · 2006 · 35 citations · High-confidence link
  • Meperidine for dystocia during the first stage of labor: A randomized controlled trial.
    American journal of obstetrics and gynecology · 2004 · 33 citations · High-confidence link
  • Effect of meperidine on uterine contractility during pregnancy and prelabor.
    American journal of obstetrics and gynecology · 1967 · 14 citations · High-confidence link

Outcome Measures

OutcomeResultp-value
PRIMARY
The Duration of Active Phase of Labour
249; 304 0.029 sig
SECONDARY
Total Duration of Labour
273; 331
SECONDARY
Duration of the Second Stage of Labour
24; 27

Eligibility Criteria

Inclusion Criteria

  • gestational age between 38 and 42 weeks
  • live fetus
  • cephalic presentation
  • in active phase of labour

Exclusion Criteria

  • placenta previa, placental abruption
  • caesarean section or any uterine scarring
  • multiple gestation
  • fetal macrosomia (≥4000 g)
  • meperidine allergy
  • use any kind of labour induction or augmentation before on admission for delivery in our hospital
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01555671) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search